Brief: Anavex Initiates Regulatory Submission of Oral Blarcamesine for Alzheimer’s Disease to European Medicines Agency
20/11/2023 13:20
Nov 20 (Reuters) - Anavex Life Sciences Corp AVXL.O :
* ANAVEX INITIATES REGULATORY SUBMISSION OF ORAL
BLARCAMESINE FOR
ALZHEIMER’S DISEASE TO EUROPEAN MEDICINES AGENCY (EMA)
Source text for Eikon: ID:nGNXGcbvt
Further company coverage: AVXL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Anavex Life Sciences
See all newsBrief: Anavex Provides Corporate Update, Announces Completion Of Clinical Conduct Of Adme And Ddi Clinical Studies
Brief: Anavex Receives FDA Clearance Of Its Ind Application For Blarcamesine In Fragile X Syndrome
Brief: Glass Lewis Recommends Anavex Stockholders To Vote For PVG’s Director Nominees
Brief: PVG Calls For Replacing Anavex Board, Hiring "Experienced" CEO
Brief: Pvg Asset Management- Nominates Six Director Candidates For Anavex Board